98%
921
2 minutes
20
In the framework of dynamic marginal structural models, regimen-response curve is a function that describes the relation between the mean outcome and the parameters in the class of decision rules. The modeling choice of the regimen-response curve is crucial in constructing an optimal regime, as a misspecified model can lead to a biased estimate with questionable causal interpretability. However, the existing literature lacks methods to evaluate and compare different working models. To address this problem, we will leverage risk to assess the "goodness-of-fit" of an imposed working model. We consider the counterfactual risk as our target parameter and derive inverse probability weighting and canonical gradients to map it to the observed data. We provide asymptotic properties of the resulting risk estimators, considering both fixed and data-dependent target parameters. We will show that the inverse probability weighting estimator can be efficient and asymptotic linear when the weight functions are estimated using a sieve-based estimator. The proposed method is implemented on the LS1 study to estimate a regimen-response curve for patients with Parkinson's disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123697 | PMC |
http://dx.doi.org/10.1093/biomtc/ujaf066 | DOI Listing |
Biometrics
April 2025
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, 14620, United States.
In the framework of dynamic marginal structural models, regimen-response curve is a function that describes the relation between the mean outcome and the parameters in the class of decision rules. The modeling choice of the regimen-response curve is crucial in constructing an optimal regime, as a misspecified model can lead to a biased estimate with questionable causal interpretability. However, the existing literature lacks methods to evaluate and compare different working models.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first year of diagnosis. Numerous studies investigating microRNA (miRNA) expression patterns suggest they may be good prognostic markers.
View Article and Find Full Text PDFAm J Clin Oncol
October 2000
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia 19104, USA.
The purpose of this study was to determine the early efficacy and toxicity of a new multimodality organ-preservation regimen for locally advanced, resectable oropharyngeal squamous cell carcinoma (SCC). Patients with T3-4N0-3M0 or T2N2-3M0 oropharyngeal SCC were eligible for this Phase II study. Patients needed the physiologic reserve for surgery and technically resectable tumors.
View Article and Find Full Text PDF